NRx Pharmaceuticals, Inc. (NRXP)

NASDAQ: NRXP · IEX Real-Time Price · USD
1.38
+0.13 (10.40%)
At close: Nov 29, 2022 4:00 PM
1.43
+0.05 (3.62%)
After-hours: Nov 29, 2022 4:02 PM EST
10.4%
Market Cap 84.55M
Revenue (ttm) n/a
Net Income (ttm) -60.31M
Shares Out 66.45M
EPS (ttm) -6.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,527,027
Open 1.3
Previous Close 1.25
Day's Range 1.26 - 1.54
52-Week Range 0.49 - 8
Beta 0.70
Analysts Buy
Price Target 2.04 (+47.8%)
Earnings Date Nov 14, 2022

About NRXP

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and... [Read more]

Industry Biotechnology
Founded 2015
Employees 2
Stock Exchange NASDAQ
Ticker Symbol NRXP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for NRXP stock is "Buy." The 12-month stock price forecast is 2.04, which is an increase of 47.83% from the latest price.

Price Target
$2.04
(47.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Completed a technology transfer, submitted a new manufacturing file to the United States ("U.S.") Food and Drug Administration ("FDA"), and released new drug produced with processes designed to support ...

2 weeks ago - PRNewsWire

NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022

--Company to Host Conference Call November 14, 2022, at 8:00AM ET--- RADNOR, Pa. , Nov. 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinic...

2 weeks ago - PRNewsWire

NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process

Manufacturing files submitted to U.S. Food and Drug Administration The company has now completed its transition to U.S.-based manufacturing NRX-101 is now manufactured via a commercial-stage process RAD...

2 weeks ago - PRNewsWire

NRx Pharmaceuticals Closes $11 Million Unsecured Debt Financing

RADNOR, Pa. , Nov. 7, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage CNS biopharmaceutical company, today announced that it has ...

3 weeks ago - PRNewsWire

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference

Company to Present Corporate Update During Investor Conference, Sept. 14, 2022, at 9:00am ET RADNOR, Pa.

2 months ago - PRNewsWire

RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATION

Release of an ad hoc announcement pursuant to Art. 53 LR GENEVA and RADNOR, Pa.

3 months ago - PRNewsWire

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation

GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / August 22, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx"), t...

3 months ago - Accesswire

NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advan...

Company to Host Conference Call and Webcast August 15, 2022, at 8:30am ET RADNOR, Pa. , Aug. 15, 2022  /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"),...

3 months ago - PRNewsWire

NRx Pharmaceuticals to Report Second Quarter 2022 Results on August 15, 2022

--Company to Host Conference Call August 15th, 2022, at 8:30AM ET--- RADNOR, Pa. , Aug. 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinic...

3 months ago - PRNewsWire

NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director

Extensive experience in Law, Finance, and Management of Public and Private Biotechnology Companies Proven track record of creating value for shareholders National Science Board Presidential Appointee, 2...

4 months ago - PRNewsWire

Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorizatio...

GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief fr...

4 months ago - Accesswire

FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at ...

Focus is now on NRX-101 for Bipolar Depression with Suicidality RADNOR, Pa. , July 1, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals"), a clinical-stage biopharmace...

4 months ago - PRNewsWire

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychia...

Company to Present Corporate and Psychiatry Franchise Update During Webcast, June 27, 2022, at 7:00am ET  RADNOR, Pa. , June 23, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Phar...

5 months ago - PRNewsWire

Class Action Suit Against NRx Pharmaceuticals Dismissed

RADNOR, Pa. , June 22, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company, is pleased to announce that on June 13, 2022, t...

5 months ago - PRNewsWire

Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil

GENEVA, SWITZERLAND / ACCESSWIRE / June 13, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic reli...

5 months ago - Accesswire

NRx Pharmaceuticals Provides Update on Breakthrough Therapy Designation (BTD) Request for ZYESAMI® (aviptadil)

RADNOR, Pa. , June 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, NRx Pharmaceuticals), ("NRXP" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the...

5 months ago - PRNewsWire

NRx Pharmaceuticals Appoints Seth Van Voorhees, PhD, as Chief Financial Officer and Treasurer

RADNOR, Pa. , June 7, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, announced today that the company's Board of Directors appointed Seth Van ...

5 months ago - PRNewsWire

Why Is NRx Pharmaceuticals (NRXP) Stock Down 60% Today?

Today, investors in NRx Pharmaceuticals and NRXP stock have seen heavy selling pressure as a key trial was stopped due to futility. The post Why Is NRx Pharmaceuticals (NRXP) Stock Down 60% Today?

6 months ago - InvestorPlace

Why NRX Pharmaceuticals Shares Are Trading Lower During Premarket On Thursday?

Based on the review of approximately 460 patients, Data Safety and Monitoring Board (DSMB) determined that the evaluation of NRx Pharmaceuticals Inc's (NASDAQ: NRXP) Zyesami (aviptadil) should cease due...

6 months ago - Benzinga

Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. N...

GENEVA, SWITZERLAND / ACCESSWIRE / May 26, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF), (OTCQB:RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief fr...

6 months ago - Accesswire

NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) ...

Based on a review of nearly 75% of the target enrollment of 640 patients, most of which have reached 90 days, the Independent DSMB overseeing the ACTIV-3b (TESICO) study determined that evaluation of av...

6 months ago - PRNewsWire

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment Conference

Company to Present Corporate Update During Investor Webcast, May 24, 2022, at 7:00am ET RADNOR, Pa. , May 19, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceu...

6 months ago - PRNewsWire

NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

Company to Host Conference Call and Webcast May 16, 2022, at 8:30am ET RADNOR, Pa. , May 16, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, NRx Pharmaceuticals), a clinical-stage biopharm...

6 months ago - PRNewsWire

NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suic...

NRx Pharmaceuticals, Inc., enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial is studying patients with bipolar depression and sub-acute suicidality ...

6 months ago - PRNewsWire

NRx Pharmaceuticals to Report First Quarter 2022 Results on May 16, 2022

--Company to Host Conference Call May 16, 2022, at 8:30AM ET-- RADNOR, Pa. , May 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceu...

6 months ago - PRNewsWire